Coherus Oncology Inc’s recently made public that its Director Wahlstrom Mats unloaded Company’s shares for reported $73881.0 on May 23 ’25. In the deal valued at $0.74 per share,99,988 shares were sold. As a result of this transaction, Wahlstrom Mats now holds 0 shares worth roughly $0.0.
UBS downgraded its Coherus Oncology Inc [CHRS] rating to a Neutral from a a Buy in a research note published on August 16, 2024; the price target was decreased to $1.50 from $4. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who began to cover the stock in mid November with a ‘”an Outperform”‘ rating. Maxim Group also remained covering CHRS and has decreased its forecast on November 08, 2023 with a “Hold” recommendation from previously “Buy” rating. Citigroup started covering the stock on July 24, 2023. It rated CHRS as “a Buy”.
Price Performance Review of CHRS
On Monday, Coherus Oncology Inc [NASDAQ:CHRS] saw its stock jump 3.07% to $0.79. Over the last five days, the stock has lost -8.11%. Coherus Oncology Inc shares have fallen nearly -43.11% since the year began. Nevertheless, the stocks have fallen -56.86% over the past one year. While a 52-week high of $2.43 was reached on 01/06/25, a 52-week low of $0.66 was recorded on 05/15/25.
Levels Of Support And Resistance For CHRS Stock
The 24-hour chart illustrates a support level at 0.7473, which if violated will result in even more drops to 0.7096. On the upside, there is a resistance level at 0.8055. A further resistance level may holdings at 0.8260.
The most recent change occurred on May 01, 2023 when Truist began covering the stock and recommended ‘”a Buy”‘ rating along with a $24 price target.
